The authors declare that they have no competing interests.
MRA conceived of the study and participated in its design and coordination and drafted the manuscript. MLB participated in writing of the manuscript and the laboratory testing. SV participated in the design of the study and aided in the collection of the samples. All authors read and approved the final manuscript.
Polymorphisms within the PfATP6 gene have been indicated as potential molecular markers for artemisinin efficacy. Since 2004, the use of artemisinin combination therapy (ACT) was introduced as first-line treatment of the uncomplicated malaria cases in Suriname. The aim of this research was to determine changes in Suriname in the status of the polymorphic markers in the PfATP6 gene before and after the adoption of the ACT-regimen, particularly of the S769N mutation, which was reported to be associated with in vitro Artemether resistance in the neighboring country French Guiana.
The PfATP6 gene from Plasmodium falciparum parasites in Suriname was investigated in 28 samples using PCR amplification and restriction enzyme analysis, to assess and determine the prevalence of potentially interesting single nucleotide polymorphisms. The polymorphisms [L263E; A623E; S769N], which may be associated with the artemisinin resistant phenotype were characterized in parasites from three endemic regions before and after the adoption of the ACT-regimen. In addition, the status of these molecular markers was compared in paired P. falciparum isolates from patients with recurring malaria after controlled ACT.
All the investigated samples exhibit the wild-type genotype at all three positions; L263, A623, S769.
All investigated isolates before and after the adoption of the ACT-regimen and independent of endemic region harbored the wild-type genotype for the three investigated polymorphisms. The study revealed that decreased artemisinin susceptibility could occur independent from PfATP6 mutations, challenging the assumption that artemisinin resistance is associated with these mutations in the PfATP6 gene.
WHO: Position of WHO’s Roll Back Malaria Department on Malaria Treatment Policy. 2003, World Health Organization, www.emro.who.int/RBM/WHOPositionStatement.pdf.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ: Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009, 361: 455-467. 10.1056/NEJMoa0808859. PubMedCentralCrossRefPubMed
Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, Ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F: Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012, 379: 1960-1966. 10.1016/S0140-6736(12)60484-X. PubMedCentralCrossRefPubMed
Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, Socheat D, Fandeur T, Annerberg A, Christophel EM, Ringwald P: Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006, 11: 1800-1807. 10.1111/j.1365-3156.2006.01739.x. CrossRefPubMed
Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, Do Rosário V, Cravo P: Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother. 2006, 50: 480-489. 10.1128/AAC.50.2.480-489.2006. PubMedCentralCrossRefPubMed
Pillai DR, Lau R, Khairnar K, Lepore R, Via A, Staines HM, Krishna S: Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections. Malar J. 2012, 11: 131-10.1186/1475-2875-11-131. PubMedCentralCrossRefPubMed
Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, Das D, Phyo AP, Lwin KM, Pukrittayakamee S, Lee SJ, Saisung S, Koecharoen K, Nguon C, Day NPJ, Socheat D, White NJ: Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 2010, 54: 2886-2892. 10.1128/AAC.00032-10. PubMedCentralCrossRefPubMed
WHO: The status of drug-resistant malaria along the Thailand-Myanmar border. 2012, World Health Organization, http://www.searo.who.int/LinkFiles/Malaria_drug-resistance-MMMR-THA-border-April-2012.pdf.
ABS: Zevende algemene volks- en woningtelling in Suriname: landelijke resultaten volume I, demografische en sociale karakteristieken. Suriname in Cijfers no 213-2005/02. Paramaribo. 2005, Suriname: Algemeen Bureau voor de Statistiek/Censuskantoor
WHO: Report on the situation of malaria in the Americas, 2008. 2008, Suriname: World Health Organization, http://new.paho.org/hq/index.php?option=com_content%26task=view%26id=2459%26Itemid=2000., Chapter 19
Vreden SGS, Jitan JK, Eersel MGM, Keenswijk WG, Danso T, Bretas G, Ruebush TK: Antimalarial efficacy in Suriname. 2001, http://www.usaidami.org/extras/vreden1.pdf., -2006: Implications of evidence-based therapy change
Ferreira ID, Martinelli A, Rodrigues LA, Do Carmo LE, Do Rosário EV, Póvoa MM, Cravo P: Plasmodium falciparum from Pará state (Brazil) shows satisfactory in vitro response to artemisinin derivatives and absence of the S769N mutation in the SERCA‒type PfATPase6. Trop Med Int Health. 2008, 13: 199-207. 10.1111/j.1365-3156.2007.01991.x. CrossRefPubMed
Price RN, Uhlemann A-C, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004, 364: 438-447. 10.1016/S0140-6736(04)16767-6. PubMedCentralCrossRefPubMed
- Status of potential Pf ATP6 molecular markers for artemisinin resistance in Suriname
Malti R Adhin
Stephen G Vreden
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II